Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

July 2012 - FRMC

07/22/2013

Tim Casey

Tim Casey
  Chicago—Patients who took tamoxifen for 10 years had a reduced disease recurrence and breast cancer mortality compared with a group receiving the drug for 5 years, according to a randomized, phase 3 trial that began >20 years ago. The...
  Chicago—Patients who took tamoxifen for 10 years had a reduced disease recurrence and breast cancer mortality compared with a group receiving the drug for 5 years, according to a randomized, phase 3 trial that began >20 years ago. The...
  Chicago—Patients who took...
07/22/2013
First Report Managed Care
07/23/2012

Kevin L. Carter

Kevin L. Carter
Studies of animal models have found that proprotein convertase subtilisin/kexin 9 (PCSK9), one of the serine proteases, has a role in the post-translational regulation of LDL-receptor activity. PCSK9, which is synthesized primarily in the...
Studies of animal models have found that proprotein convertase subtilisin/kexin 9 (PCSK9), one of the serine proteases, has a role in the post-translational regulation of LDL-receptor activity. PCSK9, which is synthesized primarily in the...
Studies of animal models have...
07/23/2012
First Report Managed Care
07/23/2012

Tim Casey

Tim Casey
Chicago—After 30 months, patients with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia who took bosutinib had superior efficacy and safety results compared with those who received imatinib, according to updated...
Chicago—After 30 months, patients with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia who took bosutinib had superior efficacy and safety results compared with those who received imatinib, according to updated...
Chicago—After 30 months,...
07/23/2012
First Report Managed Care
07/23/2012

Tim Casey

Tim Casey
Chicago—A phase 3, international, randomized trial of patients with hormone-sensitive metastatic prostate cancer found that overall survival was inferior in those who had intermittent androgen deprivation therapy compared with those who...
Chicago—A phase 3, international, randomized trial of patients with hormone-sensitive metastatic prostate cancer found that overall survival was inferior in those who had intermittent androgen deprivation therapy compared with those who...
Chicago—A phase 3,...
07/23/2012
First Report Managed Care
07/23/2012

Tim Casey

Tim Casey
Chicago—An analysis of an ongoing phase 2 study found that patients with nonmetastatic, castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA) reacted well to and managed toxicities when taking orteronel, an...
Chicago—An analysis of an ongoing phase 2 study found that patients with nonmetastatic, castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA) reacted well to and managed toxicities when taking orteronel, an...
Chicago—An analysis of an...
07/23/2012
First Report Managed Care
07/23/2012

Tim Casey

Tim Casey
Chicago—The first phase 3 study to evaluate trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer found that the investigational antibody drug conjugate had superior efficacy and safety compared with an...
Chicago—The first phase 3 study to evaluate trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer found that the investigational antibody drug conjugate had superior efficacy and safety compared with an...
Chicago—The first phase 3 study...
07/23/2012
First Report Managed Care
07/23/2012

Tim Casey

Tim Casey
Chicago—A phase 3 study found that nab-paclitaxel and ixabepilone were not superior to standard treatment (paclitaxel) in patients with chemotherapy-naïve metastatic breast cancer who also received bevacizumab. Hope S. Rugo, MD, professor of...
Chicago—A phase 3 study found that nab-paclitaxel and ixabepilone were not superior to standard treatment (paclitaxel) in patients with chemotherapy-naïve metastatic breast cancer who also received bevacizumab. Hope S. Rugo, MD, professor of...
Chicago—A phase 3 study found...
07/23/2012
First Report Managed Care
07/23/2012

Tim Casey

Tim Casey
Chicago—Patients with advanced stage non–small cell lung cancer (NSCLC) who took the investigational oral agent afatinib had a significantly longer progression-free survival compared with those who received a standard combination chemotherapy...
Chicago—Patients with advanced stage non–small cell lung cancer (NSCLC) who took the investigational oral agent afatinib had a significantly longer progression-free survival compared with those who received a standard combination chemotherapy...
Chicago—Patients with advanced...
07/23/2012
First Report Managed Care
07/23/2012

Tim Casey

Tim Casey
Orlando—When cancer patients undergo chemotherapy treatments, they face numerous challenges, among them nausea and vomiting. Physicians and nurses sometimes underestimate how many patients will have these side effects, according to Charles...
Orlando—When cancer patients undergo chemotherapy treatments, they face numerous challenges, among them nausea and vomiting. Physicians and nurses sometimes underestimate how many patients will have these side effects, according to Charles...
Orlando—When cancer patients...
07/23/2012
First Report Managed Care

News

News
07/23/2012

Kevin L. Carter

Kevin L. Carter
A series of somatic mutations that affect the progression and development of acute myeloid leukemia (AML) has recently been discovered. The prognostic relevance of cytogenetic abnormalities has led to the widespread adoption of risk...
A series of somatic mutations that affect the progression and development of acute myeloid leukemia (AML) has recently been discovered. The prognostic relevance of cytogenetic abnormalities has led to the widespread adoption of risk...
A series of somatic mutations...
07/23/2012
First Report Managed Care

Advertisement

Advertisement

Advertisement